Severe Acute Respiratory News and Research

RSS

Impact of an omicron outbreak at a private gathering in the Faroe Islands

New findings suggest that the Omicron variant has potent immune-escape capabilities, putting even newly boosted patients at risk of infection.

29 Dec 2021

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

A new study found that the presence of a subset of antibodies with broad neutralizing activities against all circulating variants of concern in the three-dose vaccines' memory B-derived antibody repertoire suggests that the Omicron/future variants infection may elicit selective and rapid recall of humoral responses, conferring secondary protection directed by memory etched in the immune system.

29 Dec 2021

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Research suggests that a single booster dose of NVX-CoV2373 given approximately six months after the primary series induced significant increases in humoral antibodies, while also exhibiting an acceptable safety profile.

29 Dec 2021

Booster dose of mRNA vaccines found crucial in protecting against SARS-CoV-2 Omicron variants

A new study shows that Omicron is more infectious than any of the other variants and that booster vaccines, especially mRNA vaccines, are capable of neutralizing Omicron variants of pseudoviruses.

29 Dec 2021

Estimating the epidemic potential of SARS-CoV-2 Omicron variant in South Korea

Researchers in South Korea and France have conducted an analysis on individuals infected with Omicron variant (B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to estimate the epidemic potential and long-term prospects of this virus in circulation. They have found that the basic reproduction number (R0) for this variant is 1.90, while the mean serial interval is 2.22 days.

28 Dec 2021

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Now in new research, scientists from the University of Leicester have been investigating how these mutations alter the affinities of RBDs to ACE2.

28 Dec 2021

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

Researchers assess vaccine effectiveness of two and three doses of BNT162b2 against SARS-CoV-2 infections and COVID-19-related hospital admission.

28 Dec 2021

SARS-CoV-2 infection induces robust and cross-reactive immune responses in children

Researchers compare the convalescent humoral and cellular immune responses between children and adults infected with SARS-CoV-2.

28 Dec 2021

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

Researchers from the University of Colorado Anschutz Medical Campus have been investigating the changes imparted on the Gamma variant by three RBD mutations.

28 Dec 2021

An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older

A new study posted to the medRxiv* pre-print server included individuals over 13 years of age receiving the third vaccine dose to further evaluate the association between myocarditis and COVID-19 vaccination or infection. The study took place from December 1, 2020, to November 15, 2021.

28 Dec 2021

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization.

28 Dec 2021

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. Their paper is currently available on the medRxiv* preprint server while it undergoes peer review.

28 Dec 2021

Third BNT162b2 dose effectively neutralizes SARS-CoV-2 Omicron pseudovirus

The findings reveal that the Omicron neutralizing titers induced by the third vaccine dose are comparable to that achieved against the original Wuhan strain (wild-type SARS-CoV-2) by the two-dose regimen. The study is currently available on the medRxiv* preprint server while awaiting peer review.

28 Dec 2021

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

A new research letter evaluates whether the estimated vaccine effectiveness changes against infection over time.

28 Dec 2021

Double-dose mRNA COVID vaccines effective among dialysis patients

Researchers assess the impact of lesser initial vaccine response and subsequent waning antibody levels on clinical outcomes among maintenance dialysis.

28 Dec 2021

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

The Omicron spike is relatively poorly cleaved and impaired in mediating cell-cell fusion and syncytia formation, contrary to predictions.

28 Dec 2021

Pfizer vaccine associated with lower risk of SARS-CoV-2 infection and hospitalization in middle-aged adults

New findings suggest that the Pfizer-BioNTech mRNA COVID-19 vaccines provide extra protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than AstraZeneca.

24 Dec 2021

Pfizer-BioNTech booster shot may offer better immunity than a two-dose regimen

A new study suggests that the immune response against severe acute respiratory syndrome coronavirus 2 is greater with a three-dose regimen than a two-dose regimen.

24 Dec 2021

New study provides a mutational analysis of SARS-CoV-2

A new study investigates mutational waves in structural and non-structural protein evolutions of SARS-CoV-2 to better understand the virus’s evolution and epidemiology.

24 Dec 2021

Children with pre-existing immunity to common cold demonstrate better protection against COVID-19

New data shows that, compared to adults, children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) preferentially activate pre-existing acquired immunity to prevalent common cold coronaviruses that cross-react with SARS-CoV-2 and protect them from severe disease.

24 Dec 2021

Severe Acute Respiratory News and Research

Impact of an omicron outbreak at a private gathering in the Faroe Islands

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Booster dose of mRNA vaccines found crucial in protecting against SARS-CoV-2 Omicron variants

Estimating the epidemic potential of SARS-CoV-2 Omicron variant in South Korea

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

SARS-CoV-2 infection induces robust and cross-reactive immune responses in children

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

Third BNT162b2 dose effectively neutralizes SARS-CoV-2 Omicron pseudovirus

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

Double-dose mRNA COVID vaccines effective among dialysis patients

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

Pfizer vaccine associated with lower risk of SARS-CoV-2 infection and hospitalization in middle-aged adults

Pfizer-BioNTech booster shot may offer better immunity than a two-dose regimen

New study provides a mutational analysis of SARS-CoV-2

Children with pre-existing immunity to common cold demonstrate better protection against COVID-19

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News